Trade Names:Synagis- Injection, solution 100 mg/mL
Neutralizing and fusion-inhibitory activity against respiratory syncytial virus (RSV), inhibiting RSV replication.
The half-life is 20 days in children younger than 24 mo of age.
Prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.
Standard considerations.
IM 15 mg/kg monthly through the RSV season. Give doses of more than 1 mL in divided doses.
Store at 36° to 46°F in original containers. Do not freeze. Discard any unused portion.
None well documented.
None well documented.
Rash.
Otitis media (36%); rhinitis (27%).
Hernia (4%); diarrhea; vomiting; gastroenteritis.
Increased AST (3%).
Upper respiratory tract infection (51%); cough; wheezing.
Fever (27%); anaphylaxis, injection-site reaction, severe acute hypersensitivity (including dyspnea, cyanosis, respiratory failure, urticaria, pruritus, angioedema, hypotonia, and unresponsiveness); severe thrombocytopenia (postmarketing).
MonitorMonitor patient for signs and symptoms of allergic reaction. |
Category C .
Severe hypersensitivity reactions on initial exposure and reexposure to palivizumab rarely have been reported. Be prepared to treat appropriately.
Not indicated for adult use.
Palivizumab serum levels are decreased after cardiopulmonary bypass. Administer a dose of palivizumab as soon as possible after the cardiopulmonary bypass procedure, even if sooner than a month from the previous dose. Thereafter, doses should be administered monthly.
Administer with caution to patients with thrombocytopenia or any coagulation disorder caused by risk of bleeding at IM injection site.
No data available.
Copyright © 2009 Wolters Kluwer Health.